DARÉ to PLAY™ Webinar: Transforming Women's Arousal Solutions
A groundbreaking approach for enhancing women’s sexual comprehension and experiences - introducing an innovative topical formulation utilizing the active component also found in Viagra.
This unique treatment is anticipated to be made available upon prescription in the near future.
San Diego has seen a progressive shift in women's health discussions thanks to Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company dedicated to addressing the unmet needs in the realm of women's health. Today, we highlight the information shared during a live webinar, which creatively introduced the DARE to PLAY™ difference.
The session, aptly named “The DARE to PLAY™ Difference: The Sildenafil Cream That Raises the Bar,” was presented in partnership with The National Association of Nurse Practitioners in Women’s Health (NPWH). It focused on a revolutionary innovation - a topical sildenafil formulation tailored specifically for women. This product aims to enhance genital blood flow and sexual response, utilizing the same active ingredient as Viagra.
Leading the dialogue were three esteemed experts in the field of sexual health: Dr. Irwin Goldstein, who has devoted over two decades to studying sildenafil, along with his colleagues, spotlighting how DARE to PLAY™ is reshaping the narrative surrounding female sexual arousal. It finally offers women a reliable, evidence-based option for enhancing their sexual experiences.
Key Highlights Discussed:
- Understanding the crucial role of genital blood flow in female arousal and how DARE to PLAY™ provides targeted intervention.
- Reviewing clinical studies that showcase significant improvements in arousal, orgasm, and desire among women using DARE to PLAY™.
- Exploring the proprietary formulation of DARE to PLAY™ and its clinical implications.
- Unpacking how Daré's expertise in formulation and clinical development aligns with the goal of addressing significant gaps within women's health.
Participants in the webinar had the opportunity to express their interest in joining the product alert list, which will ensure they are notified prior to the sildenafil cream's launch, projected for the forthcoming months.
This informative session was tailored for clinicians, investors, and women seeking credible, scientifically-backed solutions for improving their sexual health.
Webinar Details:
Title: The DARE to PLAY™ Difference: The Sildenafil Cream That Raises the Bar
Speakers:
- Rose Hartzell-Cushanick, AASECT Certified Sex Therapist
- Sue Goldstein, CCRC, CSE, IF, Past President of the International Society for the Study of Women’s Sexual Health (ISSWSH)
- Irwin Goldstein, MD, IF, Founding Editor of The Journal of Sexual Medicine and past president of ISSWSH
Date: Upcoming date to be determined.
Time: More details to follow.
About Daré Bioscience
Daré Bioscience is driven by its unwavering commitment to redefine women’s health standards. The company is dedicated to accelerating the introduction of innovative, evidence-based solutions that address long-standing gaps in women's healthcare. The primary focus areas include contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health, and menopause.
Daré has already made strides in this field, with their first FDA-approved product, XACIATO™ (clindamycin phosphate) vaginal gel, specifically aimed at treating bacterial vaginosis. The product, which is under a global license agreement with Organon, is just one example of Daré's dedication to improving women's health outcomes. Additionally, their pipeline includes Ovaprene®, a hormone-free contraceptive, the sildenafil cream aimed at addressing female sexual arousal disorder (FSAD), and DARE-HRT1, an intravaginal hormone therapy solution for menopausal women.
The leadership at Daré Bioscience has been recognized for their contributions to women’s health innovation. Their initiatives have garnered attention globally, with their CEO being named among the most influential in biopharma from notable organizations.
Investors are encouraged to stay informed on Daré's advancements by following their Investor Relations section online, where important updates about the company's progress and product developments are routinely shared.
Frequently Asked Questions
What is DARE to PLAY™?
DARE to PLAY™ is a topical formulation of sildenafil developed specifically for women to enhance sexual arousal and response.
When will DARE to PLAY™ be available?
It is expected to be available by prescription in the near future.
Who are the key speakers in the webinar?
The webinar features Rose Hartzell-Cushanick, Sue Goldstein, and Dr. Irwin Goldstein, all experts in sexual health.
What are the benefits of DARE to PLAY™?
Clinical evidence suggests improvements in arousal, orgasm, and overall sexual satisfaction for women using the cream.
How can I stay updated on Daré Bioscience’s products?
You can join their product alert list or follow their updates on the company’s Investor Relations webpage.
